Kolon Pharma has officially entered the medical aesthetics market by signing a CDMO agreement with CGMedtex for an hECM (extracellular matrix) skin booster based on mADM (acellular dermal matrix). The move signals growing OEM/ODM opportunities in Korea’s advanced biomaterial supply chain, relevant for overseas distributors seeking differentiated injectable products.
Kolon Pharma-CGMedtex CDMO Deal
Kolon Pharma announced on June 16 that it has signed a CDMO contract with CGMedtex for the manufacture and supply of an hECM skin booster. The product leverages CGMedtex’s proprietary micronization technology to preserve bioactivity while enhancing skin penetration and procedure convenience. It is based on ECM biomaterial technology, a rising trend in medical aesthetics. The partnership is part of Kolon Pharma’s strategy to transform into a patient-centered life-care company beyond traditional pharmaceuticals. The appointment of CEO Jeon Seung-ho, who previously led the FDA approval and global expansion of Daewoong’s botulinum toxin Nabota, is expected to accelerate the aesthetic business. Under the deal, CGMedtex will handle development, production, and regulatory approvals, while Kolon Pharma will focus on domestic sales and marketing. The company aims to expand into medical devices, digital healthcare, and regenerative medicine, offering integrated lifecycle solutions. A Kolon Pharma official stated: "This CDMO contract with CGMedtex is an important milestone in our evolution into a comprehensive life-care company. We will secure differentiated competitiveness in the aesthetic market with the excellent mADM-based hECM skin booster and continuously complete our portfolio."
Inibio Showcases INIBO at AMWC Korea 2026
Inibio announced on June 16 that it will participate as a diamond sponsor at AMWC Korea 2026, held June 19-20 at the Grand InterContinental Seoul Parnas. The company will operate an independent booth and host a sponsored symposium to promote its botulinum toxin brand INIBO.
On June 20, a symposium titled "Clinical Diversification of Botulinum Toxin INIBO (CCUG7968): Refinement and Expansion of Therapeutic Approaches" will feature presentations on facial indications, HA-based synergy, and dermotoxin-based calf reduction. Dr. Lee Won-ki of Beautique Clinic will discuss INIBO’s precision and HA synergy, while Dr. Hwang Seung-guk of Seven Days Plastic Surgery will present on anatomical train-based calf reduction using dermotoxin. Inibio is also running a "Global Expert Program" for medical professionals and partners from Brazil, China, and Peru, including facility tours, live seminars, and product introductions. An Inibio official emphasized: "This AMWC Korea participation is a key opportunity to imprint INIBO’s clinical value and manufacturing competitiveness globally. With recent Peru market approval, we will accelerate entry into Brazil and other global markets."
Huons Meditech Targets Southeast Asia at AMUSE 2026
Huons Meditech, a subsidiary of Huons Global, participated in AMUSE 2026, an international medical beauty exhibition held June 12-14 in Jakarta, Indonesia. The company showcased its key products to strengthen its presence in the growing Southeast Asian aesthetic market. Featured products included the DermaShine DuoRF, a motorized drug injection pump with low-power RF energy delivery, and the Premium 9-Pin Needle, a disposable sterile needle for skin boosters. Both devices have obtained Indonesian Ministry of Health medical device approvals. The DermaShine DuoRF is optimized for high-viscosity polymer skin booster injection, featuring an improved pressure-sensing auto-injection system that reduces pain and minimizes drug loss. The Premium 9-Pin Needle optimizes bevel angle and length to reduce leakage and patient discomfort. During the exhibition, the products received high interest for meeting local market demands. Huons Meditech held meetings to expand cooperation with existing clients and explore new business opportunities. CEO Ha Chang-woo stated: "Through this exhibition, we introduced core products and laid the foundation for expanding our presence in Southeast Asia. We will continue to actively participate in overseas exhibitions to strengthen brand value and global position."
Source: Read the original report | Published: June 16, 2026